Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (191-200 of 1,123) with videos related to

Pageof 113
Sort By:
Journal of Medical Economics|May 21, 2025
Cost-effectiveness of enzalutamide with androgen-deprivation therapy (ADT) versus ADT alone for the treatment of high-risk biochemically recurrent non-metastatic castration-sensitive prostate cancer in CanadaArmen Aprikian, Fred Saad, Ewa Wywial, et al.
Cancer Immunology, Immunotherapy : CII|May 22, 2010
Phenotypic characterization of chronic inflammation in a rare case of endobronchial carcinomaPhilippe O Gannon, Simon Turcotte, Jean-Luc Laporte, et al.
The Canadian Journal of Urology|July 5, 2006
Does prolonging the time to prostate cancer surgery impact long-term cancer control: a systematic review of the literatureFred Saad, Antonio Finelli, George Dranitsaris, et al.
The Prostate|July 15, 2005
Independent role of phosphoinositol-3-kinase (PI3K) and casein kinase II (CK-2) in EGFR and Her-2-mediated constitutive NF-kappaB activation in prostate cancer cellsCécile Le Page, Ismael Hervé Koumakpayi, Laurent Lessard, et al.
Journal of Medical Economics|April 26, 2022
Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in CanadaFred Saad, Andrew Chilelli, Benny Hui, et al.
Communications Biology|March 23, 2022
Pre-activation of autophagy impacts response to olaparib in prostate cancer cellsMaxime Cahuzac, Patricia Langlois, Benjamin Péant, et al.
European Journal of Cancer (Oxford, England : 1990)|September 6, 2023
The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancerNeeraj Agarwal, Tian Zhang, Eleni Efstathiou, et al.
Biopreservation and Biobanking|June 22, 2016
A Simple Variable Number of Tandem Repeat-Based Genotyping Strategy for the Detection of Handling Errors and Validation of Sample Identity in BiobanksCharles Pellerin, Ginette McKercher, Armen G Aprikian, et al.
BMC Public Health|September 20, 2015
Metabolic syndrome and prostate cancer risk in a population-based case-control study in Montreal, CanadaAudrey Blanc-Lapierre, Andrea Spence, Pierre I Karakiewicz, et al.
Biomedical Optics Express|January 8, 2019
Combining high wavenumber and fingerprint Raman spectroscopy for the detection of prostate cancer during radical prostatectomyKelly Aubertin, Joannie Desroches, Michael Jermyn, et al.
Pageof 113

Showing results (191-200 of 1,123) with videos related to

Sort By:
Pageof 113
Journal of Medical Economics|May 21, 2025
Cost-effectiveness of enzalutamide with androgen-deprivation therapy (ADT) versus ADT alone for the treatment of high-risk biochemically recurrent non-metastatic castration-sensitive prostate cancer in CanadaArmen Aprikian, Fred Saad, Ewa Wywial, et al.
Cancer Immunology, Immunotherapy : CII|May 22, 2010
Phenotypic characterization of chronic inflammation in a rare case of endobronchial carcinomaPhilippe O Gannon, Simon Turcotte, Jean-Luc Laporte, et al.
The Canadian Journal of Urology|July 5, 2006
Does prolonging the time to prostate cancer surgery impact long-term cancer control: a systematic review of the literatureFred Saad, Antonio Finelli, George Dranitsaris, et al.
The Prostate|July 15, 2005
Independent role of phosphoinositol-3-kinase (PI3K) and casein kinase II (CK-2) in EGFR and Her-2-mediated constitutive NF-kappaB activation in prostate cancer cellsCécile Le Page, Ismael Hervé Koumakpayi, Laurent Lessard, et al.
Journal of Medical Economics|April 26, 2022
Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in CanadaFred Saad, Andrew Chilelli, Benny Hui, et al.
Communications Biology|March 23, 2022
Pre-activation of autophagy impacts response to olaparib in prostate cancer cellsMaxime Cahuzac, Patricia Langlois, Benjamin Péant, et al.
European Journal of Cancer (Oxford, England : 1990)|September 6, 2023
The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancerNeeraj Agarwal, Tian Zhang, Eleni Efstathiou, et al.
Biopreservation and Biobanking|June 22, 2016
A Simple Variable Number of Tandem Repeat-Based Genotyping Strategy for the Detection of Handling Errors and Validation of Sample Identity in BiobanksCharles Pellerin, Ginette McKercher, Armen G Aprikian, et al.
BMC Public Health|September 20, 2015
Metabolic syndrome and prostate cancer risk in a population-based case-control study in Montreal, CanadaAudrey Blanc-Lapierre, Andrea Spence, Pierre I Karakiewicz, et al.
Biomedical Optics Express|January 8, 2019
Combining high wavenumber and fingerprint Raman spectroscopy for the detection of prostate cancer during radical prostatectomyKelly Aubertin, Joannie Desroches, Michael Jermyn, et al.
Pageof 113